RenMab™: Best-in-class fully human antibody platform

Key Features

1. Full human heavy chain and kappa light chain V(D)J loci substitution in situ

2. Fully human antibody repertoire diversity

Human heavy chain IGHV germline usage of naive RenLite™ mice

Human heavy chain IGHV germline usage of naive RenLite™ mice

Human heavy chain IGHV germline usage of naive RenLite™ mice

Human heavy chain IGHV germline usage of naive RenLite™ mice

Human heavy chain IGHV germline usage of naive RenLite™ mice

3. Robust immune response comparable to wild type mouse

Validation Data

1. High binding affinity at sub-nanomolar range

The binding affinity of RenMab™ derived antibodies are comparable to antibodies generated from wild type mouse and chimeric antibodies.

2. RenMab™ mice show similar immune cell profiles to wild type mice

3. RenMab™ mice show overall normal B cell development with slight delay compared to wild type mice.

4. RenMab™ antibodies undergo successful class switching similar to wild type mice

Similar serum levels of Ig isotypes and IgG subtypes indicates successful class switch.

Learn more: RenMab™/RenLite™ Technical Data Sheet

Download brochure

RenMice® HiTS Platform

The RenMice® HiTS (Hyperimmune Target Specific) Platform consists of a library of RenMice® each with a specific target gene knocked out. These mice are designed to elicit robust immune responses against homologous proteins and generate antibodies that bind to broader epitopes.